Key result
AutoHealth prospective study evaluates continuous multimodal in-vehicle sensors against medical-grade cardiovascular monitoring.
Why the study?
Continuous physiological monitoring outside clinical environments remains limited by usability, reproducibility, and user adherence, whereas vehicles offer a semi-controlled setting for unobtrusive multimodal sensing.
Does continuous multimodal in-vehicle cardiovascular monitoring accurately estimate vital signs compared to medical-grade reference measurements in adults?
Observational (n=120)
No
Does continuous multimodal in-vehicle cardiovascular monitoring accurately estimate vital signs compared to medical-grade reference measurements in adults?
Answers are grounded in this paper and cite their sources.
The AutoHealth study will provide foundational clinical evidence on the feasibility and accuracy of continuous in-vehicle cardiovascular monitoring.
Background Continuous physiological monitoring outside clinical environments remains limited by usability, reproducibility and user adherence. Vehicles offer a semi-controlled setting enabling unobtrusive multimodal sensing during everyday mobility. The Automotive Health Proof of Concept Trial (AutoHealth) investigates real-world feasibility and accuracy of continuous in-vehicle cardiovascular monitoring using integrated optical, electrical and acoustic sensors benchmarked against medical-grade reference standards. Methods/Design AutoHealth is a prospective, observational cohort study at Charité – Universitätsmedizin Berlin enrolling adults across five predefined cohorts: healthy individuals, patients with an elevated cardiometabolic risk, HFpEF, HFrEF and persistent atrial fibrillation. Participants undergo comprehensive baseline phenotyping followed by a structured in-vehicle session comprising static and dynamic driving segments and predefined physical and cognitive stress tasks. Synchronized biosignals including rPPG, steering-wheel ECG, phonocardiography and voice-derived features are compared with clinical reference measurements. The primary endpoint is the median absolute percentage error (MAPE) of in-vehicle vital sign estimates versus reference measurements, with successful performance defined a priori as MAPE ≤10%. Secondary endpoints include the proportion of measurements meeting predefined clinical accuracy thresholds, arrhythmia detection performance, characterization of autonomic stress response and correlations with functional mobility metrics. The study adheres to STROBE and SPIRIT-AI guidelines and is registered in the German Clinical Trials Register. Discussion AutoHealth is designed to provide a prospective clinical validation of continuous multimodal cardiovascular monitoring inside a modified production vehicle under real-world driving conditions and reproducible closed-course testing. Study findings will characterize feasibility, performance and translational potential of Automotive Health as a scalable prevention and remote physiological monitoring paradigm.
No takes yet. Share an insight, caveat, or question.
Naumann et al. (2026) conducted an observational in Healthy, elevated cardiometabolic risk, HFpEF, HFrEF, and persistent atrial fibrillation (n=120). Continuous multimodal in-vehicle cardiovascular monitoring vs. Medical-grade reference measurements was evaluated on Median absolute percentage error (MAPE) of in-vehicle vital sign estimates versus reference measurements. Continuous multimodal in-vehicle cardiovascular monitoring is being prospectively validated for accuracy against medical-grade reference standards in the AutoHealth study, with results pending.
Synapse has enriched 10 related papers. Consider them for comparative context: